Mechanism of action
Discover RECARBRIO: A broad-coverage carbapenem/novel BLI combination
Learn about:
Discover RECARBRIO


The clinical significance of in vitro data is unknown.
RECARBRIO is not active against most isolates containing metallo-beta-lactamases (MBLs), some oxacillinases with carbapenemase activity, as well as certain alleles of GES.
Activity against key pathogens with certain mechanisms of resistance
RECARBRIO has shown activity against some of the most prevalent mechanisms of resistance for P. aeruginosa and select mechanisms of resistance for Enterobacteriaceae.

RECARBRIO is not active against most isolates containing metallo-beta-lactamases (MBLs), some oxacillinases with carbapenemase activity, as well as certain alleles of GES.
The clinical significance of in vitro data is unknown.
Antimicrobial activity
RECARBRIO™ (imipenem, cilastatin, and relebactam) has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections.
- Acinetobacter calcoaceticus-baumannii complex
- Enterobacter cloacae
- Escherichia coli
- Haemophilus influenzae
- Klebsiella aerogenes
- Klebsiella oxytoca
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Serratia marcescens
- Enterobacter cloacae
- Escherichia coli
- Klebsiella aerogenes
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Citrobacter freundii
- Enterobacter cloacae
- Escherichia coli
- Klebsiella aerogenes
- Klebsiella oxytoca
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Bacteroides caccae
- Bacteroides fragilis
- Bacteroides ovatus
- Bacteroides stercoris
- Bacteroides thetaiotaomicron
- Bacteroides uniformis
- Bacteroides vulgatus
- Fusobacterium nucleatum
- Parabacteroides distasonis
Abbreviations: AmpC, Ambler class C beta-lactamase; BLI, betalactamase inhibitor; ESBL, extended-spectrum beta-lactamase; GES, Guiana extended-spectrum beta-lactamase; KPC, Klebsiella pneumoniae carbapenemase; OprD, outer membrane protein porin D.
1. Karlowsky JA et al. J Glob Antimicrob Resist.2020;21:223-228.